A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00703742
Recruitment Status : Completed
First Posted : June 23, 2008
Last Update Posted : June 27, 2011
Chinese Academy of Sciences
Information provided by:
Kunming Medical University

Brief Summary:

The purpose of this study is:

  1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
  2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
  3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
  4. to find possible predispose to MDD
  5. to explore the DNA methylation status in depression;

Condition or disease Intervention/treatment Phase
Depression Depression Secondary to Other Disease Drug: Escitalopram Not Applicable

Detailed Description:
  1. to explore the pathology of depression
  2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
  3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Health Services Research
Official Title: A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
Study Start Date : June 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants
U.S. FDA Resources

Arm Intervention/treatment
Experimental: A,1
A: Escitalopram, 20 mg/day,8weeks
Drug: Escitalopram
A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Primary Outcome Measures :
  1. change of fMRI after medication [ Time Frame: baseline, 4 weeks, 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • DSM-IV Major Depression or Dysthymia
  • Age 18-65
  • Physically healthy
  • Drug-free

Exclusion Criteria:

  • Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
  • History of Psychosis or Epilepsy
  • Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
  • Bipolar I
  • Need for wash-out from effective treatment in order to participate
  • Pregnant
  • High suicide risk
  • Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00703742

China, Yunnan
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China, 650031
Sponsors and Collaborators
Kunming Medical University
Chinese Academy of Sciences
Study Director: Xu Xiufeng Kunming Medical University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kunming Medical College Identifier: NCT00703742     History of Changes
Other Study ID Numbers: Kunming MC
First Posted: June 23, 2008    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents